How a Single Gene-Editing Treatment Cut LDL Cholesterol for a Year: What the Early Studies Show

# What happened

# Which treatments and targets were studied

Two distinct approaches produced the most-noted early results:

• CTX310 (CRISPR-Cas9): A first-in-human Phase 1 study edited the ANGPTL3 gene in the liver. ANGPTL3 influences levels of LDL cholesterol and triglycerides. At the highest dose group, later reports described about a 52.5% reduction in LDL after one year and marked triglyceride drops.

• VERVE 102 (base editing): A Phase 1 interim analysis reported by Verve Therapeutics targeted PCSK9, a gene that affects how the liver clears LDL. In an analysis of roughly 35 participants, the highest dose produced up to about a 62% mean LDL reduction.

# Why the numbers matter — and where they don't

However, LDL change is a surrogate outcome. The trials to date are small and designed mainly to assess safety and biological effect. They have not shown that editing ANGPTL3 or PCSK9 with these approaches reduces cardiovascular events such as heart attacks, strokes, or cardiovascular mortality.

# Safety and durability questions left open

Available follow-up suggests the cholesterol-lowering effect persisted through the reported periods, but the long-term durability beyond current follow-up is unknown. Researchers also need to monitor for rare or delayed safety issues tied to permanent genetic changes, such as unintended edits or long-term liver effects.

Current standard-of-care options include statins, PCSK9 inhibitor drugs, and inclisiran. Those treatments require ongoing administration and have established clinical histories showing reductions in cardiovascular events for many patients.

Gene-editing approaches aim to change the underlying pathway so a single treatment might produce sustained effects. That represents a different therapeutic strategy, but it is still experimental and has not yet demonstrated clinical endpoint benefit.

# What comes next

• Larger, longer trials are required to confirm safety across broader patient populations and to test whether LDL reductions translate into fewer heart attacks and strokes.
• Continued follow-up will be needed to assess how durable the cholesterol-lowering effects remain and to detect any delayed adverse events.
• Even if confirmed, these approaches would enter a treatment landscape that already includes effective, approved options with proven outcomes.

# Bottom line